Serotonin noradrenaline reuptake inhibitors: A new generation of treatment for anxiety disorders

International Journal of Psychiatry in Clinical Practice

Volumn 10, Issue SUPPL. 2, 2006, Pages 12-15

  Baldwin, David S ^a  

^a UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

Author keywords

Anxiety disorders; SNRI; SSRI; Treatment

Indexed keywords

4 HYDROXY 3 METHOXYPHENYLETHYLENE GLYCOL; ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; BENZODIAZEPINE DERIVATIVE; BUSPIRONE; DIAZEPAM; DULOXETINE; IMIPRAMINE; MILNACIPRAN; MONOAMINE; MONOAMINE OXIDASE INHIBITOR; NEW DRUG; NORADRENALIN; PAROXETINE; SEROTONIN; SEROTONIN 1A AGONIST; SEROTONIN AGONIST; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN TRANSPORTER; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRICYCLIC ANTIDEPRESSANT AGENT; UNCLASSIFIED DRUG; VENLAFAXINE;

AMYGDALOID NUCLEUS; ANXIETY; ANXIETY DISORDER; ARTICLE; CEREBROSPINAL FLUID ANALYSIS; CHRONIC DISEASE; CLINICAL TRIAL; COMORBIDITY; DEPRESSION; DOSE RESPONSE; DRUG DEPENDENCE; DRUG EFFICACY; HUMAN; LETHARGY; MEMORY DISORDER; META ANALYSIS; NEUROTRANSMISSION; NORADRENALIN RELEASE; NORADRENERGIC SYSTEM; PANIC; POSTTRAUMATIC STRESS DISORDER; PRIORITY JOURNAL; PROTEIN BINDING; SEROTONINERGIC SYSTEM; SOMNOLENCE; WITHDRAWAL SYNDROME;

EID: 33646696174     PISSN: 13651501     EISSN: 14711788     Source Type: Journal    
DOI: 10.1080/13651500600637056     Document Type: Article

References (37)

1. Wittchen H-U, Jacobi F. Eur Neuropsychopharmacol 2005;15:357-76.
2. Kessler RC, McGonagle KA, Zhao S, et al. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey. Arch Gen Psychiatry 1994;51:8-19.
3. Stein DJ, Stahl S. Serotonin and anxiety: Current models. Int Clin Psychopharmacol 2000;15(Suppl 2):S1-6.
4. Snyder SH. Neurobiology: Serotonin sustains serenity. Nature 2002;416:377-80.
5. Sen S, Burmeister M, Ghosh D. Meta-analysis of the association between a serotonin transporter promoter polymorphism (5-HTTLPR) and anxiety-related personality traits. Am J Med Genet B Neuropsychiatr Genet 2004;127:85-9.
6. Schinka JA, Busch RM, Robichaux-Keene N. A meta-analysis of the association between the serotonin transporter gene polymorphism (5-HTTLPR) and trait anxiety. Mol Psychiatry 2004;9:197-202.
7. You JS, Hu SY, Chen B, Zhang HG. Serotonin transporter and tryptophan hydroxylase gene polymorphisms in Chinese patients with generalized anxiety disorder. Psychiatr Genet 2005;15:7-11.
8. Ressler KJ, Nemeroff CB. Role of serotonergic and noradrenergic systems in the pathophysiology of depression and anxiety disorders. Depress Anxiety 2000;12(Suppl 1):2-19.
9. Gorman JM. Treatment of generalized anxiety disorder. J Clin Psychiatry 2002;63(Suppl 8):17-23.
10. Pollack MH, Zaninelli R, Goddard A, et al. Paroxetine in the treatment of generalized anxiety disorder: Results of a placebo-controlled, flexible-dosage trial. J Clin Psychiatry 2001;62:350-7.
11. Rocca P, Fonzo V, Scotta M, et al. Paroxetine efficacy in the treatment of generalized anxiety disorder. Acta Psychiatr Scand 1997;95:444-50.
12. Sevy S, Papadimitriou GN, Surmont DW, et al. Noradrenergic function in generalized anxiety disorder, major depressive disorder, and healthy subjects. Biol Psychiatry 1989;25:141-52.
13. Brunello N, Blier P, Judd LL, et al. Noradrenaline in mood and anxiety disorders: Basic and clinical studies. Int Clin Psychopharmacol 2003;18:191-202.
14. Feldman S, Weidenfeld J. The excitatory effects of the amygdala on hypothalamo-pituitary-adrenocortical responses are mediated by hypothalamic norepinephrine, serotonin, and CRF-41. Brain Res Bull 1998;45:389-93.
15. Tanaka M, Yoshida M, Emoto H, et al. Noradrenaline systems in the hypothalamus, amygdala and locus coeruleus are involved in the provocation of anxiety: basic studies. Eur J Pharmacol 2000;405:397-406.
16. Silverstone PH. Qualitative review of SNRIs in anxiety. J Clin Psychiatry 2004;65(Suppl 17):19-28.
17. Baldwin DS, Anderson IM, Nutt DJ, et al. Evidence-based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British Association for Psychopharmacology. J Psychopharmacol 2005;19:567-96.
18. Davidson JR, Meoni P, Haudiquet V, et al. Achieving remission with venlafaxine and fluoxetine in major depression: Its relationship to anxiety symptoms. Depress Anxiety 2002;16:4-13.
19. Allgulander C, Mangano R, Zhang J, et al. Efficacy of venlafaxine ER in patients with social anxiety disorder: A double-blind, placebo-controlled, parallel-group comparison with paroxetine. Hum Psychopharmacol 2004;19:387-96.
20. Rickels K, Pollack MH, Sheehan DV, et al. Efficacy of extended-release venlafaxine in non-depressed outpatients with generalized anxiety disorder. Am J Psychiatry 2000;157:968-74.
21. Gelenberg AJ, Lydiard RB, Rudolph RL, et al. Efficacy of venlafaxine extended-release capsules in nondepressed outpatients with generalized anxiety disorder: A 6-month randomized controlled trial. J Am Med Assoc 2000;283:3082-8.
22. Davidson JR, DuPont RL, Hedges D, et al. Efficacy, safety, and tolerability of venlafaxine extended release and buspirone in outpatients with generalized anxiety disorder. J Clin Psychiatry 1999;60:528-35.
23. Hackett D, Haudiquet V, Salinas E. A method for controlling for a high placebo response rate in a comparison of venlafaxine XR and diazepam in the short-term treatment of patients with generalised anxiety disorder. Eur Psychiatry 2003;18:182-7.
24. Allgulander C, Hackett D, Salinas E. Venlafaxine extended release (ER) in the treatment of generalised anxiety disorder: Twenty-four-week placebo-controlled dose-ranging study. Br J Psychiatry 2001;179:15-22.
25. Pollack MH, Meoni P, Otto MW, Simon N, Hackett D. Predictors of outcome following venlafaxine extended-release treatment of DSM-IV generalized anxiety disorder: a pooled analysis of short- and long-term studies. J Clin Psychopharmacol 2003;23:250-9.
26. Whitaker T, Bradwejn J, Emilien G, et al. Treatment of panic disorder with venlafaxine XR. Poster presented at the meeting of the American College of Neuropsychopharmacology 2003; San Juan, Puerto Rico.
27. Pollack MH, Emilien G, Tzanis E, et al. Venlafaxine XR and paroxetine in the short-term treatment of panic disorder. Poster presented at meeting of the World Federation for the Society of Biological Psychiatry; 2004; Sydney, Australia.
28. Liebowitz MR, Asnis G, Tzanis E, et al. A placebo-controlled trial of venlafaxine XR in the short-term treatment of panic disorder. Poster presented at the meeting of the Collegium Internationale Neuropsychopharmacologicum; 2004; Paris, France.
29. Rickels K, Mangano R, Khan A. A double-blind, placebo-controlled study of a flexible dose of venlafaxine ER in adult outpatients with generalized social anxiety disorder J Clin Psychopharmacol 2004;24:488-96.
30. Liebowitz MR, Mangano RM, Bradwejn J, et al. A randomized controlled trial of venlafaxine extended release in generalized social anxiety disorder. J Clin Psychiatry 2005;66:238-47.
31. Liebowitz MR, Gelenberg AJ, Munjack D. Venlafaxine extended release vs placebo and paroxetine in social anxiety disorder. Arch Gen Psychiatry 2005;62:190-8.
32. Davidson J, Lipschitz A, Musgnung J. A double-blind comparison of venlafaxine XR, sertraline, and placebo in the treatment of PTSD. Poster presented at the meeting of the New Clinical Drug Evaluation Unit; 2004; Phoenix, AZ.
33. Davidson J, Baldwin DS, Stein DJ, et al. A 6-month study of venlafaxine XR versus placebo in the treatment of post-traumatic stress disorder. Eur Neuropsychopharmacol 2005;15(Suppl 3):S545.
34. Denys D, van der Wee N, van Megen HJ, et al. A double blind comparison of venlafaxine and paroxetine in obsessive-compulsive disorder. J Clin Psychopharmacol 2003;23:568-75.
35. Tsukamoto T, Kondoh R, Ichikawa K. Efficacy and safety of milnacipran in the treatment of generalized anxiety disorder: An open study. Int J Psychiatry Clin Pract 2004;8:255-8.
36. Cia AH, Brizuela JA, Cascardo E, et al. Pilot study of clonazepam and milnacipran in the treatment of panic disorder with co-morbid major depression. Poster presented at the 5th International Forum on Mood and Anxiety, Vienna, Austria. Int J Psychiatry Clin Pract 2005;9:321:11.
37. Dunner DL, Goldstein DJ, Mallinckrodt C, et al. Duloxetine in treatment of anxiety symptoms associated with depression. Depress Anxiety 2003;18:53-61.